FAQ

Wy 41195

Known as: Wy 41,195, Wy-41,195, Wy-41195 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1982-1986
01219821986

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
1986
Review
1986
The development of Wy-41,195, an orally effective antiallergic drug in animal models
Introduction Disodium cromoglycate (DSCG) administered by aerosol is well established as a prophylactic treatment for asthma… (More)
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
1985
1985
The topical effects of Wy-41,195 [2-cyano-3-(methylamino)phenylamino] oxoacetic acid, sodium salt and disodium cromoglycate in the rat passive eyelid anaphylaxis.
Wy-41,195 demonstrated significant inhibitory effects (54-60%) when administered topically at 0.25-2% concentrations in a rat… (More)
Is this relevant?
1984
1984
The effects of antiallergic and bronchodilator drugs on platelet-activating factor (PAF-acether) induced bronchospasm and platelet aggregation
Platelet activating factor (PAF-acether) is a potential mediator of asthma and inflammation. Recently, the suggestion was made… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
1984
1984
Modulation of sulfur dioxide-induced airways hyperresponsiveness in the conscious dog.
Brief exposure of conscious dogs to 30 ppm SO2 directly into the lungs resulted in a transient bronchoconstriction followed by a… (More)
Is this relevant?
1982
1982
The pharmacologic profile of wy-41,195, a new orally effective antiallergic agent.
[2-Cyano-3-(methylamino)phenylamino]oxoacetic acid, sodium salt (Wy-41,195) was found to be a potent oral inhibitor (viz., ED50… (More)
Is this relevant?